Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease
The findings suggest that patients prefer safe and efficacious treatments and DBT may be an acceptable option for those who have failed an advanced therapy for IBD. We demonstrate the value of building on existing evidence and designing efficient DCE studies to address knowledge gaps to improve IBD care.
Authors
- Melissa Marko
- Jui‐Chen Yang (ORCID: https://orcid.org/0000-0001-8229-6578)
- Matthew J. Wallace (ORCID: https://orcid.org/0000-0002-6250-4998)
- Laura M. Bozzi (ORCID: https://orcid.org/0000-0001-5326-6521)
- John D. Lynch (ORCID: https://orcid.org/0000-0002-6358-1610)
- Ellen M. Janssen (ORCID: https://orcid.org/0000-0003-0405-4252)
- Meenakshi Bewtra (ORCID: https://orcid.org/0000-0002-6489-7043)
- F. Reed Johnson (ORCID: https://orcid.org/0000-0002-7572-2150)
- Anna Sheahan
Institutions
- Johnson & Johnson (United States) (US)
- Duke University (US)
- Clinical Research Institute (US)
- Janssen (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.14309/ajg.0000000000003397
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82